These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28748315)

  • 1. Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients.
    Hadoux J; Terroir M; Leboulleux S; Deschamps F; Al Ghuzlan A; Hescot S; Tselikas L; Borget I; Caramella C; Déandréis D; Goere D; De Baere T; Schlumberger M; Baudin E
    Horm Cancer; 2017 Dec; 8(5-6):330-337. PubMed ID: 28748315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
    Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
    Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
    Ayala-Ramirez M; Chougnet CN; Habra MA; Palmer JL; Leboulleux S; Cabanillas ME; Caramella C; Anderson P; Al Ghuzlan A; Waguespack SG; Deandreis D; Baudin E; Jimenez C
    J Clin Endocrinol Metab; 2012 Nov; 97(11):4040-50. PubMed ID: 22965939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas.
    Oh DY; Kim TW; Park YS; Shin SJ; Shin SH; Song EK; Lee HJ; Lee KW; Bang YJ
    Cancer; 2012 Dec; 118(24):6162-70. PubMed ID: 22736481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma.
    Kong G; Grozinsky-Glasberg S; Hofman MS; Callahan J; Meirovitz A; Maimon O; Pattison DA; Gross DJ; Hicks RJ
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3278-3287. PubMed ID: 28605448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience.
    Shilkrut M; Bar-Deroma R; Bar-Sela G; Berniger A; Kuten A
    Am J Clin Oncol; 2010 Feb; 33(1):79-82. PubMed ID: 19704370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features and outcomes of metastatic pheochromocytoma treated by cytotoxic chemotherapy.
    Fujiwara Y; Ohmoto A; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Yuasa T; Yonese J; Takahashi S
    Endocr J; 2021 Jun; 68(6):671-681. PubMed ID: 33518616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
    J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up.
    Stenman A; Zedenius J; Juhlin CC
    Surgery; 2019 Nov; 166(5):901-906. PubMed ID: 31239074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
    Gonias S; Goldsby R; Matthay KK; Hawkins R; Price D; Huberty J; Damon L; Linker C; Sznewajs A; Shiboski S; Fitzgerald P
    J Clin Oncol; 2009 Sep; 27(25):4162-8. PubMed ID: 19636009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
    Wachtel H; Hutchens T; Baraban E; Schwartz LE; Montone K; Baloch Z; LiVolsi V; Krumeich L; Fraker DL; Nathanson KL; Cohen DL; Fishbein L
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4661-70. PubMed ID: 32877928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.
    O'Kane GM; Ezzat S; Joshua AM; Bourdeau I; Leibowitz-Amit R; Olney HJ; Krzyzanowska M; Reuther D; Chin S; Wang L; Brooks K; Hansen AR; Asa SL; Knox JJ
    Br J Cancer; 2019 Jun; 120(12):1113-1119. PubMed ID: 31105270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlling Tumor Progression with Cyclophosphamide, Vincristine, and Dacarbazine Treatment Improves Survival in Patients with Metastatic and Unresectable Malignant Pheochromocytomas/Paragangliomas.
    Asai S; Katabami T; Tsuiki M; Tanaka Y; Naruse M
    Horm Cancer; 2017 Apr; 8(2):108-118. PubMed ID: 28108930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic pheochromocytomas and paragangliomas: where are we?
    Prinzi N; Corti F; Torchio M; Niger M; Antista M; Pagani F; Beninato T; Pulice I; Rossi RE; Coppa J; Cascella T; Giacomelli L; Di Bartolomeo M; Milione M; de Braud F; Pusceddu S
    Tumori; 2022 Dec; 108(6):526-540. PubMed ID: 35593402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial.
    Nasca V; Prinzi N; Coppa J; Prisciandaro M; Oldani S; Ghelardi F; Conca E; Capone I; Busico A; Perrone F; Tamborini E; Sabella G; Greco G; Greco FG; Tafuto S; Procopio G; Morano F; Niger M; Maccauro M; Milione M; de Braud F; Pietrantonio F; Pusceddu S
    Eur J Cancer; 2024 Sep; 209():114276. PubMed ID: 39128186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management and outcome of metastatic pheochromocytomas/paragangliomas: a monocentric experience.
    De Filpo G; Cantini G; Rastrelli G; Vannini G; Ercolino T; Luconi M; Mannelli M; Maggi M; Canu L
    J Endocrinol Invest; 2022 Jan; 45(1):149-157. PubMed ID: 34227051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma.
    Gedik GK; Hoefnagel CA; Bais E; Olmos RA
    Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):725-33. PubMed ID: 18071700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG.
    Thorpe MP; Kane A; Zhu J; Morse MA; Wong T; Borges-Neto S
    J Clin Endocrinol Metab; 2020 Mar; 105(3):e494-501. PubMed ID: 31614368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.
    Jasim S; Suman VJ; Jimenez C; Harris P; Sideras K; Burton JK; Worden FP; Auchus RJ; Bible KC
    Endocrine; 2017 Aug; 57(2):220-225. PubMed ID: 28685225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of metyrosine in pheochromocytoma/paraganglioma: a multi-center trial in Japan.
    Naruse M; Satoh F; Tanabe A; Okamoto T; Ichihara A; Tsuiki M; Katabami T; Nomura M; Tanaka T; Matsuda T; Imai T; Yamada M; Harada T; Kawata N; Takekoshi K
    Endocr J; 2018 Mar; 65(3):359-371. PubMed ID: 29353821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.